In detail, in 1 patient with HER2-/HR+ tumor (treated with chemotherapy only; cT2/cN1) and in 4 patients with triple negative tumors, all treated with chemotherapy only (1 patient cT2/cN0, 1 patient cT2/cN3, 1 patient cT3/cN1 and 1 patient cT4/cN0). This evidence concerns the gene ERBB2 and neoplasm.